1.1 Current evidence on the efficacy of Grenz rays therapy for inflammatory skin conditions is very limited and is difficult to assess because reported patient groups are heterogeneous and patient numbers are small. With regard to safety, there is some concern about the risk of skin malignancy in the long term. Therefore, clinicians wishing to use Grenz rays therapy should do so only in research involving controlled trials, closely observed case series and/or contribution to a register. Studies should include clear definitions of treatment indications and quality-of-life measures.
1.2 Only carefully selected patients whose inflammatory skin conditions are unresponsive to other treatments should be offered Grenz rays therapy under the research conditions referred to in section 1.1.
1.3 The Institute may review this procedure in the light of further research.